Pharma, Biotech & Medtech Industry

CLINICAL TRIALS IN NORDIC COUNTRIES IS BASED ON TRUST, HIGH QUALITY AND EFFICIENCY

The Nordic countries are famous for high quality clinical expertise, advanced research infrastructures, and for well-organized health care systems that encompass entire populations. In addition, the Nordic countries can provide efficient participant recruitment and retention due to citizen“s fundamental trust to health care systems and well-functioning collaboration with local healthcare providers. These elelment together ensures the success of conducting clinical research in Nordic countries that improve the competitiveness of European clinical research.

The Nordic region constitutes a population of approximately 28 million people, in five countries with similar legal and healthcare systems. The region holds great potential for clinical research, both from an academic and an industry perspective. All Nordic countries have somewhat similar health care standards and clinical practices. The paediatric population of individual Nordic countries may be too small for paediatric clinical trials alone, but utilizing the network collaboration of the Nordic countries the recruitment potential can substantially increase by proving larger child population size (approx. 5,6 million children between 0 and 18 years of age) comparable to large European countries.

NordicPedMed aims to develop new innovative approaches built on the strengths of our historical collaboration and experience of paediatric clinical research. The core function is based on study coordination, avoiding unnecessary trials in children, and building up scientific and administrative competence to help the recruitment of patients for clinical trials.

NORDICPEDMED SERVICES

The operational model of the NORDICPEDMED network is based on the network’s own Investigators Registry that helps to quickly identify and offer experts for requested services.

  • Feasibilities
  • Conduct of pediatric clinical trials
  • Co-operation and research projects (investigators and research groups)
  • Early phase drug development; consultation (PIPs)
  • Protocol design and improvement
  • Consultations on written protocols
  • Consultations and statements by clinical experts (Expert Boards in Finland)
  • Consultations by experts in pediatric clinical pharmacology and drug formulation
  • Consultations related to development, research and registration of pediatric medicines